| [1] |
李俊东，刘韬，万挺．上皮性卵巢癌规范化维持治疗专家共识[J]. 今日药学，2023, 33(4): 241-247.
|
| [2] |
|
| [3] |
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review [J]. Semin Oncol Nurs, 2019, 35(2): 151-156. DOI: 10.1016/j.soncn.2019.02.001.
|
| [4] |
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine [J]. CA Cancer J Clin， 2019， 69(4): 280-304. DOI: 10.3322/caac.21559.
|
| [5] |
Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma [J]. Am J Pathol, 2002, 160(4): 1223-1228. DOI: 10.1016/s0002-9440(10)62549-7.
|
| [6] |
Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system [J]. Am J Surg Pathol, 2004, 28(4): 496-504. DOI: 10.1097/00000478-200404000-00009.
|
| [7] |
Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis [J]. Am J Pathol, 2004, 164(5): 1511-1518. DOI: 10.1016/s0002-9440(10)63708-x.
|
| [8] |
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(4): 284-296. DOI: 10.3322/caac.21456.
|
| [9] |
|
| [10] |
Hollis L. Molecular characteristics and clinical behaviour of epithelial ovarian cancers [J]. Cancer Lett, 2023, 28: 555. DOI: 10.1016/j.canlet.2023.216057.
|
| [11] |
Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: state of the science [J]. Gynecol Oncol, 2020, 156(3): 715-725. DOI: 10.1016/j.ygyno.2019.12.033.
|
| [12] |
Babaier A, Mal H, Alselwi W, et al. Low-grade serous carcinoma of the ovary: the current status [J]. Diagnostics (Basel), 2022, 12(2): 458. DOI: 10.3390/diagnostics12020458.
|
| [13] |
Wang Y, Hong S, Mu J, et al. Tubal origin of " ovarian" low-grade serous carcinoma: a gene expression profile study [J]. J Oncol, 2019, 2019: 8659754. DOI: 10.1155/2019/8659754.
|
| [14] |
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma [J]. Clin Cancer Res, 2022, 28(20): 4456-4465. DOI: 10.1158/1078-0432.CCR-21-4183.
|
| [15] |
Gershenson DM, Sun CC, Westin SN, et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes [J]. Gynecol Oncol, 2022, 165(3): 560-567. DOI: 10.1016/j.ygyno.2021.11.019.
|
| [16] |
ElNaggar A, Robins D, Baca Y, et al. Genomic profiling in low grade serous ovarian cancer: identification of novel markers for disease diagnosis and therapy [J]. Gynecol Oncol, 2022, 10: S0090-8258(22)01850-9. DOI: 10.1016/j.ygyno.2022.09.022.
|
| [17] |
Cheasley D, Nigam A, Zethoven M, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities [J]. J Pathol, 2021, 253(1): 41-54. DOI： 10.1002/path.5545.
|
| [18] |
中国医师协会妇产科医师分会妇科肿瘤专业委员会(学组)，马晓欣，向阳．卵巢子宫内膜样癌临床诊治中国专家共识(2023年版)[J]. 中国实用妇科与产科杂志， 2023, 39(4): 445-451. DOI: 10.19538/j.fk2023040113. |
| [19] |
Hollis RL, Thomson JP, Stanley B, et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome [J]. Nat Commun, 2020, 11(1): 4995. DOI: 10.1038/s41467-020-18819-5.
|
| [20] |
Cybulska P, Paula ADC, Tseng J, et al. Molecular profiling and molecular classification of endometrioid ovarian carcinomas [J]. Gynecol Oncol, 2019, 154(3): 516-523. DOI: 10.1016/j.ygyno.2019.07.012.
|
| [21] |
Pierson WE, Peters PN, Chang MT, et al. An integrated molecular profile of endometrioid ovarian cancer [J]. Gynecol Oncol, 2020, 157(1): 55-61. DOI: 10.1016/j.ygyno.2020.02.011.
|
| [22] |
Hollis RL, Stanley B, Thomson JP, et al. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification [J]. NPJ Precis Oncol, 2021, 5(1): 47. DOI: 10.1038/s41698-021-00187-y.
|
| [23] |
Hollis RL, Stanley B, Iida Y, et al. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma [J]. Gynecol Oncol, 2019, 155(2): 318-323. DOI: 10.1016/j.ygyno.2019.09.001.
|
| [24] |
Zyla RE, Olkhov-Mitsel E, Amemiya Y, et al. CTNNB1 mutations and aberrant β-catenin expression in ovarian endometrioid carcinoma: correlation with patient outcome [J]. Am J Surg Pathol, 2021, 45(1): 68-76. DOI: 10.1097/PAS.0000000000001553.
|
| [25] |
|
| [26] |
Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective [J]. Int J Gynecol Cancer, 2021, 31(4): 605-616. DOI: 10.1136/ijgc-2020-001656.
|
| [27] |
Prat J. New insights into ovarian cancer pathology [J]. Ann Oncol, 2012, 23 (Suppl 10): x111-x117. DOI: 10.1093/annonc/mds300.
|
| [28] |
|
| [29] |
Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma [J]. N Engl J Med, 2019, 380(13): 1256-1266. DOI: 10.1056/NEJMra1813254.
|
| [30] |
Kato N, Kamataki A, Kurotaki H. Methylation profile of imprinted genes provides evidence for teratomatous origin of a subset of mucinous ovarian tumours [J]. J Pathol, 2021, 254(5): 567-574. DOI: 10.1002/path.5702.
|
| [31] |
Cheasley D, Wakefield MJ, Ryland GL, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma [J]. Nat Commun, 2019, 10(1): 3935. DOI: 10.1038/s41467-019-11862-x.
|
| [32] |
Meagher NS, Gorringe KL, Wakefield M, et al. Gene-expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes [J]. Clin Cancer Res, 2022, 28(24): 5383-5395. DOI: 10.1158/1078-0432.CCR-22-1206.
|
| [33] |
|
| [34] |
Kurman RJ, Ie-Ming Shih. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded [J]. Am J Pathol, 2016, 186(4): 733-747. DOI: 10.1016/j.ajpath.2015.11.011.
|
| [35] |
Govindarajan M, Wohlmuth C, Waas M, et al. High-through put approaches for precision medicine in high-grade serous ovarian cancer [J]. J Hematol Oncol, 2020, 13(1): 134. DOI: 10.1186/s13045-020-00971-6.
|
| [36] |
Lisio MA, Fu L, Goyeneche A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints [J]. Int J Mol Sci, 2019, 20(4): 952. DOI: 10.3390/ijms20040952.
|
| [37] |
Hollis RL, Meynert AM, Michie CO, et al. Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification [J]. Clin Cancer Res, 2022, 28(16): 3546-3556. DOI: 10.1158/1078-0432.CCR-22-0368.
|
| [38] |
Millstein J, Budden T, Goode EL，et al. Prognostic gene expression signature for high-grade serous ovarian cancer [J]. Ann Oncol, 2020, 31(9): 1240-1250. DOI: 10.1016/j.annonc.2020.05.019.
|
| [39] |
Hollis RL, Croy I, Churchman M, et al. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma [J]. Br J Cancer, 2022, 127(6): 1034-1042. DOI: 10.1038/s41416-022-01874-8.
|
| [40] |
王桂业，陈琼，谢奇朋．血清人附睾蛋白4，糖链抗原125及卵巢恶性肿瘤风险算法在上皮性卵巢癌二元论分型中的应用价值[J].中国卫生检验杂志，2020, 30(2): 5.
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
中国医院协会妇产医院分会妇科肿瘤专业学组，王建东，王玉东. 预防性输卵管切除术的中国专家共识(2021)[J]. 中国实用妇科与产科杂志， 2021, 37(8): 826-831. DOI: 10.19538/j.fk2021080110. |
| [46] |
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2021, 19(2): 191-226. DOI: 10.6004/jnccn.2021.0007.
|
| [47] |
Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: binimetinib versus physician′s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum [J]. J Clin Oncol, 2020, 38(32): 3753-3762. DOI: 10.1200/JCO.20.01164.
|
| [48] |
Gershenson DM, Miller A, Brady WE et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial [J]. Lancet, 2022, 399(10324): 541-553. DOI: 10.1016/S0140-6736(21)02175-9.
|